Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
An-Li YuYi-Chieh ChenCheng-Hsuan TsaiYuan-Kun Aden WuMao-Yuan M SuChia-Hung ChouChia-Tung ShunHsueh-Wen HsuehJimmy Jyh-Ming JuangMing-Jen LeePing-Huei TsengChia-Hua HsuSung-Tsang HsiehChi-Lun KoMei-Fang ChengChi-Chao ChaoYen-Hung LinPublished in: Journal of the American Heart Association (2024)
The volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.